FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

Sherif Farag, Ian W. Flinn, Rama Modali, Teresa A. Lehman, Donn Young, John C. Byrd

Research output: Contribution to journalArticle

175 Citations (Scopus)

Abstract

In follicular lymphoma (FL), genomic polymorphisms corresponding to the expression of valine (V) or phenylalanine (F) at amino acid 158 of FcγRIIIa alter the binding affinity of immunoglobulin G1 (IgG1) to the receptor and have been associated with varied responses to rituximab. We examined FcγRIIIa polymorphisms of 30 CLL patients with the phenotypes V/ V (n = 6), V/F (n = 12), and F/F (n = 12) treated with thrice-weekly rituximab (375 mg/m2) for 4 weeks to correlate polymorphism type with infusion toxicity and response. Infusion toxicity (grade 3 or greater or hypoxia/hypotension requiring transient cessation of therapy) was observed equally among the groups (VN, 50%; V/F, 33%; F/F, 41.6%; P = .78). The response to rituximab was also similar among the different polymorphism phenotypes (V/V, 33%; V/F, 41.6%; F/F, 50%). These data suggest that FcγRIIIa polymorphisms are not predictive of response in CLL and that, unlike the case with FL, mechanisms of tumor clearance other than antibody-dependent cellular cytotoxicity may be more important.

Original languageEnglish (US)
Pages (from-to)1472-1474
Number of pages3
JournalBlood
Volume103
Issue number4
DOIs
StatePublished - Feb 15 2004
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Polymorphism
Follicular Lymphoma
Cells
Phenotype
Valine
Toxicity
Phenylalanine
Hypotension
Immunoglobulins
Amino Acids
Cytotoxicity
Antibodies
Tumors
Rituximab
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. / Farag, Sherif; Flinn, Ian W.; Modali, Rama; Lehman, Teresa A.; Young, Donn; Byrd, John C.

In: Blood, Vol. 103, No. 4, 15.02.2004, p. 1472-1474.

Research output: Contribution to journalArticle

Farag, Sherif ; Flinn, Ian W. ; Modali, Rama ; Lehman, Teresa A. ; Young, Donn ; Byrd, John C. / FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. In: Blood. 2004 ; Vol. 103, No. 4. pp. 1472-1474.
@article{685b8687fdfc4da5a9b8d2c8fe8790aa,
title = "FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia",
abstract = "In follicular lymphoma (FL), genomic polymorphisms corresponding to the expression of valine (V) or phenylalanine (F) at amino acid 158 of FcγRIIIa alter the binding affinity of immunoglobulin G1 (IgG1) to the receptor and have been associated with varied responses to rituximab. We examined FcγRIIIa polymorphisms of 30 CLL patients with the phenotypes V/ V (n = 6), V/F (n = 12), and F/F (n = 12) treated with thrice-weekly rituximab (375 mg/m2) for 4 weeks to correlate polymorphism type with infusion toxicity and response. Infusion toxicity (grade 3 or greater or hypoxia/hypotension requiring transient cessation of therapy) was observed equally among the groups (VN, 50{\%}; V/F, 33{\%}; F/F, 41.6{\%}; P = .78). The response to rituximab was also similar among the different polymorphism phenotypes (V/V, 33{\%}; V/F, 41.6{\%}; F/F, 50{\%}). These data suggest that FcγRIIIa polymorphisms are not predictive of response in CLL and that, unlike the case with FL, mechanisms of tumor clearance other than antibody-dependent cellular cytotoxicity may be more important.",
author = "Sherif Farag and Flinn, {Ian W.} and Rama Modali and Lehman, {Teresa A.} and Donn Young and Byrd, {John C.}",
year = "2004",
month = "2",
day = "15",
doi = "10.1182/blood-2003-07-2548",
language = "English (US)",
volume = "103",
pages = "1472--1474",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

AU - Farag, Sherif

AU - Flinn, Ian W.

AU - Modali, Rama

AU - Lehman, Teresa A.

AU - Young, Donn

AU - Byrd, John C.

PY - 2004/2/15

Y1 - 2004/2/15

N2 - In follicular lymphoma (FL), genomic polymorphisms corresponding to the expression of valine (V) or phenylalanine (F) at amino acid 158 of FcγRIIIa alter the binding affinity of immunoglobulin G1 (IgG1) to the receptor and have been associated with varied responses to rituximab. We examined FcγRIIIa polymorphisms of 30 CLL patients with the phenotypes V/ V (n = 6), V/F (n = 12), and F/F (n = 12) treated with thrice-weekly rituximab (375 mg/m2) for 4 weeks to correlate polymorphism type with infusion toxicity and response. Infusion toxicity (grade 3 or greater or hypoxia/hypotension requiring transient cessation of therapy) was observed equally among the groups (VN, 50%; V/F, 33%; F/F, 41.6%; P = .78). The response to rituximab was also similar among the different polymorphism phenotypes (V/V, 33%; V/F, 41.6%; F/F, 50%). These data suggest that FcγRIIIa polymorphisms are not predictive of response in CLL and that, unlike the case with FL, mechanisms of tumor clearance other than antibody-dependent cellular cytotoxicity may be more important.

AB - In follicular lymphoma (FL), genomic polymorphisms corresponding to the expression of valine (V) or phenylalanine (F) at amino acid 158 of FcγRIIIa alter the binding affinity of immunoglobulin G1 (IgG1) to the receptor and have been associated with varied responses to rituximab. We examined FcγRIIIa polymorphisms of 30 CLL patients with the phenotypes V/ V (n = 6), V/F (n = 12), and F/F (n = 12) treated with thrice-weekly rituximab (375 mg/m2) for 4 weeks to correlate polymorphism type with infusion toxicity and response. Infusion toxicity (grade 3 or greater or hypoxia/hypotension requiring transient cessation of therapy) was observed equally among the groups (VN, 50%; V/F, 33%; F/F, 41.6%; P = .78). The response to rituximab was also similar among the different polymorphism phenotypes (V/V, 33%; V/F, 41.6%; F/F, 50%). These data suggest that FcγRIIIa polymorphisms are not predictive of response in CLL and that, unlike the case with FL, mechanisms of tumor clearance other than antibody-dependent cellular cytotoxicity may be more important.

UR - http://www.scopus.com/inward/record.url?scp=0842264005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842264005&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-07-2548

DO - 10.1182/blood-2003-07-2548

M3 - Article

C2 - 14563637

AN - SCOPUS:0842264005

VL - 103

SP - 1472

EP - 1474

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -